

**REMARKS**

Reconsideration and allowance are respectfully requested.

The substitute Sequence Listing enclosed herewith has been amended to facilitate its administrative processing, and not for reasons related to patentability.

I hereby state that the amendments included in the substitute Sequence Listing are supported in the application, as filed. Thus, the substitute Sequence Listing does not include new matter. An amino acid sequence was cited in the specification which did not have a SEQ ID NO. (MEEKLKA)<sub>6</sub>(MEEKMKA)<sub>2</sub> was given SEQ ID NO:108. Applicants note that claim 20 was previously cancelled and therefore not amended to cite SEQ ID NO:108.

A copy of the substitute Sequence Listing in paper and computer readable form, along with the required Statement under 37 C.F.R. 1.821(g) and 1.825(b), accompany the response to the Notice to Comply (copy enclosed).

Please charge any fees or credit any overpayment of fees which are required in connection herewith to Deposit Account No. 04-1928 (E. I. du Pont de Nemours and Company).

Respectfully submitted,



LYNNE M. CHRISTENBURY  
ATTORNEY FOR APPLICANTS  
REGISTRATION NO. 30,971  
TELEPHONE: 302-992-5481  
FACSIMILE: 302-892-1026

Dated: July 12, 2004